Working on a Plasma Therapy for COVID-19
GC Pharma signed a reservation agreement for contract COVID-19 vaccine manufacturing on Oct. 21 with the Coalition for Epidemic Preparedness Innovations (CEPI).
According to the agreement, some of the company’s production facilities in South Korea will be used for COVID-19 drug production by global enterprises supported by the CEPI. That day, the CEPI signed the same agreement with Biofabri as well. The South Korean and Spanish companies will produce one billion doses of vaccines in accordance with the agreements.
GC Pharma, which is in charge of more than 500 million doses, will produce the vaccines from March 2021 to May 2022. “We are currently working on a plasma therapy and will continue to respond to the pandemic in partnership with the CEPI,” said GC Pharma CEO Huh Eun-chul.